Skip to content
OpenCapital
Get started

Allogene Therapeutics ALLO EBIT

EBIT at other companies

Precigen logo
PrecigenPGEN
-$5.99M+73.5%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-$130.25M+12.2%
Sana Biotechnology logo
Sana BiotechnologySANA
-$48.61M+4.0%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
-$19.67M-187%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
——
Gilead Sciences logo
Gilead SciencesGILD
——

Other financials

Income statement

See full
Revenue-—
Operating income-$46.1M+29.3%
Net income-$42.6M+28.7%
EPS (diluted)-$0.18+35.7%

Balance sheet

See full
Cash & equivalents$40.6M-23.0%
Total debt$81.1M-8.9%
Total equity$278.9M-27.6%
Total assets$396.0M-22.1%

Cash flow

See full
Operating cash flow-$12.9M+75.6%
CapEx$9.0K-90.9%
Free cash flow-$12.9M+75.6%

Valuation

See full
Market cap$711.02M+164%
Enterprise value$751.47M+146%

Profitability

See full
Operating margin-1,241,813.6%-2,018,140pp
Net margin-1,170,863.6%-2,007,890pp
FCF margin-913,609.1%-1,474,890pp

Returns & leverage

See full
Return on equity-52.3%-5.7pp
Debt / equity0.3×+0.1×
Current ratio9.6×-0.1×

Where this comes from

Calculated from Allogene Therapeutics’s reported figures.

−$46.1Moperating income+$300.0Kinterest expense=-$46.09M

The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Allogene Therapeutics's ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Allogene Therapeutics's EBIT?
Allogene Therapeutics (ALLO) reported EBIT of -$46.09M in Q1 2026.
How has Allogene Therapeutics's EBIT changed year-over-year?
Allogene Therapeutics's EBIT increased by 29.3% year-over-year, from -$65.19M to -$46.09M.
What is the long-term trend for Allogene Therapeutics's EBIT?
Over 4 years (2021 to 2025), Allogene Therapeutics's EBIT has grown at a 3.6% compound annual growth rate (CAGR), from -$181.9M to -$209.32M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.